top of page

GPCR News 

Post: Blog2_Post

Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of ...

April 2022


Design Pharmaceuticals Closes $5 Million Pre-series A Round to Accelerate Commercialization of Ultrahigh Throughput Drug Discovery Platform


"April 12, 2022 07:00 AM Eastern Daylight Time

CAMBRIDGE, Mass.--Design Pharmaceuticals, a company redesigning small molecule drug discovery, today announced the closing of a pre-series A round of $5 million, including an investment of $3 million from Virtus Inspire Venture Partners. The proceeds will be used to further build the company’s discovery platform and operations. Design Pharmaceuticals’ platform is based on ultrahigh-throughput technologies that biomine drug-like molecules from natural sources, such as microbiota. These molecules are then evaluated at unprecedented speed and scale on hundreds of GPCR targets simultaneously."



2 views0 comments

Recent Posts

See All

Amgen to Acquire Chemocentryx for $4 Billion in Cash

August 2022 "THOUSAND OAKS, Calif. and SAN CARLOS, Calif., Aug. 4, 2022 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and ChemoCentryx, Inc., (NASDAQ: CCXI), a biopharmaceutical company focused on orally admin

Comments